Chi-Med Enrolls 527 Lung Cancer Patients for China Trial of Fruquintinib

Hutchison China MediTech (Chi-Med) completed patient enrollment in a China Phase III trial of fruquintinib as a treatment for patients with non-small cell lung cancer. The trial, which enrolled 527 NSCLC patients who have failed two earlier treatments, will administer fruquintinib as a single agent. Chi-Med has started a Phase II trial in NSCLC as an adjunct to Iressa ® (gefitinib) as a first-line treatment for lung cancer. The CFDA has already accepted an NDA for fruquintinib in colorectal cancer. More details.... Stock Symbol: (AIM/NSDQ: HCM) Share this with colleagues: // //